Objective: The authors aim to evaluate the challenges faced by each stakeholder for Idiopathic pulmonary fibrosis (IPF) management, including the patients, their families/caretakers, Healthcare professionals, and Healthcare policymakers and organizations in Lowmiddle income countries (LMICs) as perceived by 140 pulmonologists from 11 countries who participated in International Respiratory Forum conference 2022 in Ho Chi Minh City, Vietnam. Methodology: A predesigned structured questionnaire was developed about challenges faced by each stakeholder for IPF management. Study participants were randomly divided into four groups, and only one section of the questionnaire was distributed among the participants of each group. Results: It was ob...
International audienceBackground: Two antifibrotic drugs, pirfenidone and nintedanib, are approved b...
SummaryIdiopathic pulmonary fibrosis (IPF) is a fibrotic lung disease of unknown cause characterized...
Abstract Background The diagnosis of idiopathic pulmonary fibrosis (IPF) and other interstitial lung...
Introduction: Pulmonary fibrosis (PF) and its most common form, idiopathic pulmonary fibrosis (IPF),...
Introduction: Pulmonary fibrosis (PF) and its most common form, idiopathic pulmonary fibrosis (IPF),...
SummaryBackgroundThe present survey coordinated by the French expert centres for rare pulmonary dise...
INTRODUCTION: Idiopathic pulmonary fibrosis (IPF) is a progressive, life-threatening illness of unkn...
BACKGROUND:Idiopathic Pulmonary Fibrosis (IPF) is a chronic, progressive and life-limiting condition...
BACKGROUND: Antifibrotics are recommended for the treatment of individuals with idiopathic pulmonary...
International audienceA new survey coordinated by the French expert centres for rare pulmonary disea...
Background: Antifibrotics are recommended for the treatment of individuals with idiopathic pulmonary...
<div><p>Background</p><p>Idiopathic Pulmonary Fibrosis (IPF) is a chronic, progressive and life-limi...
Objective: To characterize the treatment of idiopathic pulmonary fibrosis (IPF) by Canadian respirol...
International audienceBackground: Two antifibrotic drugs, pirfenidone and nintedanib, are approved b...
SummaryIdiopathic pulmonary fibrosis (IPF) is a fibrotic lung disease of unknown cause characterized...
Abstract Background The diagnosis of idiopathic pulmonary fibrosis (IPF) and other interstitial lung...
Introduction: Pulmonary fibrosis (PF) and its most common form, idiopathic pulmonary fibrosis (IPF),...
Introduction: Pulmonary fibrosis (PF) and its most common form, idiopathic pulmonary fibrosis (IPF),...
SummaryBackgroundThe present survey coordinated by the French expert centres for rare pulmonary dise...
INTRODUCTION: Idiopathic pulmonary fibrosis (IPF) is a progressive, life-threatening illness of unkn...
BACKGROUND:Idiopathic Pulmonary Fibrosis (IPF) is a chronic, progressive and life-limiting condition...
BACKGROUND: Antifibrotics are recommended for the treatment of individuals with idiopathic pulmonary...
International audienceA new survey coordinated by the French expert centres for rare pulmonary disea...
Background: Antifibrotics are recommended for the treatment of individuals with idiopathic pulmonary...
<div><p>Background</p><p>Idiopathic Pulmonary Fibrosis (IPF) is a chronic, progressive and life-limi...
Objective: To characterize the treatment of idiopathic pulmonary fibrosis (IPF) by Canadian respirol...
International audienceBackground: Two antifibrotic drugs, pirfenidone and nintedanib, are approved b...
SummaryIdiopathic pulmonary fibrosis (IPF) is a fibrotic lung disease of unknown cause characterized...
Abstract Background The diagnosis of idiopathic pulmonary fibrosis (IPF) and other interstitial lung...